Re: Health-related Quality of Life of Patients With Locally Advanced or Metastatic Urothelial Cancer Treated With Enfortumab Vedotin After Platinum and PD-1/PD-L1 Inhibitor Therapy: Results From Cohort 1 of the Phase 2 EV-201 Clinical Trial Editorial Comment

被引：0
|
作者：
Chang, Sam S.
McGregor, B.
O'Donnell, P. H.
Balar, A.
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 210卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：218 / 218
页数：1
相关论文
共 50 条
  • [1] Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial
    McGregor, Bradley
    O'Donnell, Peter H.
    Balar, Arjun
    Petrylak, Daniel
    Rosenberg, Jonathan
    Yu, Evan Y.
    Quinn, David, I
    Heath, Elisabeth, I
    Campbell, Mary
    Hepp, Zsolt
    McKay, Caroline
    Steinberg, Joyce
    Regnault, Antoine
    Mazerolle, Flora
    Galsky, Matthew D.
    EUROPEAN UROLOGY, 2022, 81 (05) : 515 - 522
  • [2] EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
    O'Donnell, P.
    Galsky, M. D.
    Rosenberg, J. E.
    Petrylak, D. P.
    Balar, A. V.
    McGregor, B. A.
    Heath, E.
    Yu, E. Y.
    Quinn, D. I.
    Hahn, N. M.
    Campbell, M.
    Liang, S-Y.
    Steinberg, J.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S579 - S580
  • [3] EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
    Balar, Arjun Vasant
    McGregor, Bradley Alexander
    Rosenberg, Jonathan E.
    van der Heijden, Michiel Simon
    Park, Se Hoon
    Lee, Jae-Lyun
    Harrison, Michael Roger
    Heath, Elisabeth, I
    Stein, Mark N.
    Loriot, Yohann
    Necchi, Andrea
    Steinberg, Joyce Leta
    Liang Shang-Ying
    Kim, Eric
    Trowbridge, Janet
    Campbell, Mary S.
    Petrylak, Daniel Peter
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.
    McGregor, Bradley Alexander
    Balar, Arjun Vasant
    Rosenberg, Jonathan E.
    Van der Heijden, Michiel Simon
    Park, Se Hoon
    Lee, Jae-Lyun
    Kojima, Takahiro
    Harrison, Michael Roger
    Heath, Elisabeth I.
    Stein, Mark N.
    Loriot, Yohann
    Necchi, Andrea
    Steinberg, Joyce Leta
    Liang, Shang-Ying
    Trowbridge, Janet
    Petrylak, Daniel P.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial
    Yu, Evan Y.
    Petrylak, Daniel P.
    O'Donnell, Peter H.
    Lee, Jae-Lyun
    van der Heijden, Michiel S.
    Loriot, Yohann
    Stein, Mark N.
    Necchi, Andrea
    Kojima, Takahiro
    Harrison, Michael R.
    Park, Se Hoon
    Quinn, David, I
    Heath, Elisabeth, I
    Rosenberg, Jonathan E.
    Steinberg, Joyce
    Liang, Shang-Ying
    Trowbridge, Janet
    Campbell, Mary
    McGregor, Bradley
    Balar, Arjun, V
    LANCET ONCOLOGY, 2021, 22 (06): : 872 - 882
  • [6] Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
    McGregor, B. A.
    O'Donnell, P. H.
    Balar, A.
    Petrylak, D. P.
    Rosenberg, J. E.
    Yu, E.
    Quinn, D. I.
    Shah, S. N.
    Pinelli, J.
    Hepp, Z.
    Galsky, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial (vol 22, pg 872, 2021)
    Yu, E. Y.
    Petrylak, D. P.
    O'Donnell, P. H.
    LANCET ONCOLOGY, 2021, 22 (06): : E239 - E239
  • [8] Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
    Sayegh, N.
    Jo, Y. Jung
    Gebrael, G.
    Tripathi, N.
    Chigarira, B.
    Srivastava, A.
    Nordblad, B.
    Dal, E.
    Chehade, C. Hage
    Maughan, B. L.
    Gupta, S.
    Agarwal, N.
    Swami, U.
    ANNALS OF ONCOLOGY, 2023, 34 : S1212 - S1212
  • [9] Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
    Rosenberg, Jonathan E.
    Mamtani, Ronac
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Gurney, Howard
    Bedke, Jens
    van der Heijden, Michiel S.
    Galli, Luca
    Keam, Bhumsuk
    Masumori, Naoya
    Meran, Johannes
    O'Donnell, Peter H.
    Park, Se Hoon
    Grande, Enrique
    Sengelov, Lisa
    Uemura, Hiroji
    Skaltsa, Konstantina
    Campbell, Mary
    Matsangou, Maria
    Wu, Chunzhang
    Hepp, Zsolt
    Mckay, Caroline
    Powles, Thomas
    Petrylak, Daniel P.
    EUROPEAN UROLOGY, 2024, 85 (06) : 574 - 585
  • [10] Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la/mUC) after chemotherapy followed by a PD-1/PD-L1 checkpoint inhibitor (CPI).
    Shah, Manasee
    Devine, Jacob
    Wang, Sam
    Hepp, Zsolt
    Shah, Sonali
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345